LIMN · Liminatus Pharma Inc
United States · RS rating 93 · As of 2026-10-14
| Price | 3.25 USD |
|---|---|
| 1-day change | -4.7% |
| RS rating (overall / 1M / 3M / 12M) | 93 / 29 / 99 / 96 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 30 / 46 / 35 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +37.0% |
| Market cap (USD) | $9.0M |